S&P 500   3,108.46 (-0.38%)
DOW   27,821.09 (-0.40%)
QQQ   202.15 (-0.45%)
AAPL   263.19 (-1.16%)
FB   197.51 (-0.91%)
MSFT   149.62 (-0.51%)
GOOGL   1,301.86 (-0.82%)
AMZN   1,745.53 (-0.41%)
CGC   17.64 (+15.14%)
NVDA   211.18 (+1.53%)
MU   45.57 (-2.17%)
BABA   182.35 (-1.57%)
GE   11.39 (-0.96%)
TSLA   352.22 (-2.03%)
T   37.18 (-2.16%)
AMD   40.98 (-0.75%)
ACB   2.64 (+12.82%)
F   8.73 (-1.91%)
PRI   131.52 (-0.09%)
NFLX   305.16 (+0.85%)
BAC   32.69 (-0.76%)
GILD   64.88 (-0.18%)
DIS   146.93 (-0.98%)
S&P 500   3,108.46 (-0.38%)
DOW   27,821.09 (-0.40%)
QQQ   202.15 (-0.45%)
AAPL   263.19 (-1.16%)
FB   197.51 (-0.91%)
MSFT   149.62 (-0.51%)
GOOGL   1,301.86 (-0.82%)
AMZN   1,745.53 (-0.41%)
CGC   17.64 (+15.14%)
NVDA   211.18 (+1.53%)
MU   45.57 (-2.17%)
BABA   182.35 (-1.57%)
GE   11.39 (-0.96%)
TSLA   352.22 (-2.03%)
T   37.18 (-2.16%)
AMD   40.98 (-0.75%)
ACB   2.64 (+12.82%)
F   8.73 (-1.91%)
PRI   131.52 (-0.09%)
NFLX   305.16 (+0.85%)
BAC   32.69 (-0.76%)
GILD   64.88 (-0.18%)
DIS   146.93 (-0.98%)
S&P 500   3,108.46 (-0.38%)
DOW   27,821.09 (-0.40%)
QQQ   202.15 (-0.45%)
AAPL   263.19 (-1.16%)
FB   197.51 (-0.91%)
MSFT   149.62 (-0.51%)
GOOGL   1,301.86 (-0.82%)
AMZN   1,745.53 (-0.41%)
CGC   17.64 (+15.14%)
NVDA   211.18 (+1.53%)
MU   45.57 (-2.17%)
BABA   182.35 (-1.57%)
GE   11.39 (-0.96%)
TSLA   352.22 (-2.03%)
T   37.18 (-2.16%)
AMD   40.98 (-0.75%)
ACB   2.64 (+12.82%)
F   8.73 (-1.91%)
PRI   131.52 (-0.09%)
NFLX   305.16 (+0.85%)
BAC   32.69 (-0.76%)
GILD   64.88 (-0.18%)
DIS   146.93 (-0.98%)
S&P 500   3,108.46 (-0.38%)
DOW   27,821.09 (-0.40%)
QQQ   202.15 (-0.45%)
AAPL   263.19 (-1.16%)
FB   197.51 (-0.91%)
MSFT   149.62 (-0.51%)
GOOGL   1,301.86 (-0.82%)
AMZN   1,745.53 (-0.41%)
CGC   17.64 (+15.14%)
NVDA   211.18 (+1.53%)
MU   45.57 (-2.17%)
BABA   182.35 (-1.57%)
GE   11.39 (-0.96%)
TSLA   352.22 (-2.03%)
T   37.18 (-2.16%)
AMD   40.98 (-0.75%)
ACB   2.64 (+12.82%)
F   8.73 (-1.91%)
PRI   131.52 (-0.09%)
NFLX   305.16 (+0.85%)
BAC   32.69 (-0.76%)
GILD   64.88 (-0.18%)
DIS   146.93 (-0.98%)
Log in

UCB S A/ADR Stock Price, Forecast & Analysis (OTCMKTS:UCBJY)

$40.15
-0.13 (-0.33 %)
(As of 11/6/2019)
Today's Range
$40.15
Now: $40.15
$40.15
50-Day Range
$34.60
MA: $37.99
$40.28
52-Week Range
$34.60
Now: $40.15
$44.65
Volume113 shs
Average Volume1,510 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
UCB SA, a biopharmaceutical company, researches, develops, manufactures, sells, and distributes biopharmaceutical solutions for people living with neurology and immunology conditions. The company's core products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; and Neupro for Parkinson's disease and restless legs syndrome. It also provides Zyrtec and Xyzal for allergies; Nootropil for memory problems; and Xyrem for narcolepsy. In addition, the company's product pipeline includes Evenity for the treatment of osteoporosis; midazolam nasal spray to treat acute repetitive seizures; bimekizumab for treating psoriasis, psoriatic arthritis, and axial spondyloarthritis; and dapirolizumab pegol for systemic lupus erythematosus. Further, it is involved in developing padsevonil for the treatment of drug-resistant epilepsy; rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; UCB7858 and UCB0159 for immunology; and UCB0599 and UCB0107 for neurology. Additionally, the company engages in contract manufacturing activities. UCB SA has collaboration agreements with Sanofi and Otsuka. The company was founded in 1928 and is headquartered in Brussels, Belgium.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:UCBJY
CUSIPN/A
CIKN/A
Phone32 2 559 99 99

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees6,828
Next Earnings DateN/A
OptionableNot Optionable

Receive UCBJY News and Ratings via Email

Sign-up to receive the latest news and ratings for UCBJY and its competitors with MarketBeat's FREE daily newsletter.


UCB S A/ADR (OTCMKTS:UCBJY) Frequently Asked Questions

What is UCB S A/ADR's stock symbol?

UCB S A/ADR trades on the OTCMKTS under the ticker symbol "UCBJY."

What is the consensus analysts' recommendation for UCB S A/ADR?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for UCB S A/ADR in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for UCB S A/ADR.

Has UCB S A/ADR been receiving favorable news coverage?

Media coverage about UCBJY stock has trended somewhat positive on Wednesday, InfoTrie Sentiment reports. The research group identifies positive and negative media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. UCB S A/ADR earned a daily sentiment score of 0.8 on InfoTrie's scale. They also gave news stories about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View News Stories for UCB S A/ADR.

Who are some of UCB S A/ADR's key competitors?

Who are UCB S A/ADR's key executives?

UCB S A/ADR's management team includes the folowing people:
  • Mr. Jean-Christophe Tellier, CEO & Exec. Director (Age 60)
  • Mr. Detlef Thielgen, CFO & Exec. VP (Age 59)
  • Mr. Charl Van Zyl, COO & Exec. VP (Age 52)
  • Dr. Dhavalkumar D. Patel, Exec. VP & Chief Scientific Officer (Age 58)
  • Dr. Bharat Tewarie, Chief Marketing Officer & Exec. VP (Age 58)

How do I buy shares of UCB S A/ADR?

Shares of UCBJY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is UCB S A/ADR's stock price today?

One share of UCBJY stock can currently be purchased for approximately $40.15.

What is UCB S A/ADR's official website?

The official website for UCB S A/ADR is http://www.ucb.com/.

How can I contact UCB S A/ADR?

The company can be reached via phone at 32 2 559 99 99.


MarketBeat Community Rating for UCB S A/ADR (OTCMKTS UCBJY)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  78 (Vote Outperform)
Underperform Votes:  69 (Vote Underperform)
Total Votes:  147
MarketBeat's community ratings are surveys of what our community members think about UCB S A/ADR and other stocks. Vote "Outperform" if you believe UCBJY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe UCBJY will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/20/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel